117 related articles for article (PubMed ID: 14606360)
1. The refractory patient: new treatment options.
Schuster MW
Oncology (Williston Park); 2003 Oct; 17(10):1333-5. PubMed ID: 14606360
[No Abstract] [Full Text] [Related]
2. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
van Rhee F
Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
[No Abstract] [Full Text] [Related]
3. [Current therapy concepts in patients with multiple myeloma].
Heyll A; Schneider P; Bauser U; Kobbe G; Hünerlitürkoglu A; Aul C; Haas R
Dtsch Med Wochenschr; 2000 Oct; 125(40):1201-9. PubMed ID: 11075253
[No Abstract] [Full Text] [Related]
4. Severe neurotoxicity because of dimethyl sulphoxide following peripheral blood stem cell transplantation.
Windrum P; Morris TC
Bone Marrow Transplant; 2003 Feb; 31(4):315. PubMed ID: 12621472
[No Abstract] [Full Text] [Related]
5. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
6. [Multiple myeloma -- therapy].
Jung W; Zettl F; Schroers R
Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
[No Abstract] [Full Text] [Related]
7. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma.
Hequet O; Dumontet C; El Jaafari-Corbin A; Salles G; Espinouse D; Arnaud P; Thieblemont C; Bouafia F; Coiffier B
Bone Marrow Transplant; 2002 Mar; 29(6):544. PubMed ID: 11960281
[No Abstract] [Full Text] [Related]
8. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
Buda G; Orciuolo E; Galimberti S; Cecconi N; Petrini M
Acta Haematol; 2009; 122(1):39-41. PubMed ID: 19729887
[No Abstract] [Full Text] [Related]
10. T-cell post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation: another case and a review of the literature.
Lau LG; Tan LK; Salto-Tellez M; Koay ES; Liu TC
Bone Marrow Transplant; 2004 Nov; 34(9):821-2. PubMed ID: 15354208
[No Abstract] [Full Text] [Related]
11. [Guidelines for the diagnosis and management of multiple myeloma by the Japan Myeloma Study Group].
Shimizu K;
Rinsho Ketsueki; 2005 Jun; 46(6):424-32. PubMed ID: 16447724
[No Abstract] [Full Text] [Related]
12. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
14. Tandem bone marrow transplantation in multiple myeloma.
Musto P
N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074004
[No Abstract] [Full Text] [Related]
15. Unusual multiple myeloma cutaneous manifestation following nonmyeloablative allogeneic stem cell transplantation.
Subbiah S; O'Connell F; Kobraei KB; Ramos-Caro FA; Moreb JS
Clin Adv Hematol Oncol; 2009 Dec; 7(12):800-2. PubMed ID: 20332750
[No Abstract] [Full Text] [Related]
16. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
[TBL] [Abstract][Full Text] [Related]
17. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.
Alexanian R; Weber D; Delasalle K; Handy B; Champlin R; Giralt S
Bone Marrow Transplant; 2004 Aug; 34(3):229-34. PubMed ID: 15170166
[TBL] [Abstract][Full Text] [Related]
19. Treatment options and considerations for the newly diagnosed myeloma patient.
Rajkumar VS;
Oncology (Williston Park); 2005 Sep; 19(10):1260, 1262, 1267 passim. PubMed ID: 16285223
[No Abstract] [Full Text] [Related]
20. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
